Osmotic laxatives: complete clinical overview
Osmotic laxatives are poorly absorbed solutes that retain water in the intestinal lumen. The resulting increase in stool water and luminal volume softens faeces, distends the bowel and promotes peristalsis. They are a major class for constipation, faecal loading and bowel preparation; lactulose additionally lowers intestinal ammonia absorption in hepatic encephalopathy.
Learning objectives
- Classify osmotic laxatives and explain how each subgroup retains water in the bowel.
- Compare PEG/macrogol, lactulose, magnesium salts, sodium phosphate, sorbitol and glycerol.
- Use common adult teaching doses while recognising product- and indication-specific variation.
- Recognise renal, cardiac, electrolyte and bowel-obstruction hazards.
- Apply osmotic laxatives to chronic constipation, faecal impaction, bowel preparation and hepatic encephalopathy.
How osmotic laxatives work
A non-absorbed or poorly absorbed molecule remains in the gastrointestinal lumen and raises osmolality. Water follows into the lumen, stool becomes softer and bulkier, and intestinal stretch stimulates propulsive motility. The clinical response varies with the agent: PEG is generally gentle and predictable; lactulose is fermented by colonic bacteria and commonly causes gas; magnesium and phosphate salts can act quickly but may be systemically absorbed and disturb electrolytes.
| Subgroup | Examples | Core mechanism | Typical role |
|---|---|---|---|
| Non-absorbable polymers | Polyethylene glycol 3350 (PEG 3350, macrogol), PEG-electrolyte solutions | Polymer retains water; minimal systemic absorption. | Chronic constipation, faecal disimpaction regimens, bowel preparation. |
| Non-absorbable sugars/sugar alcohols | Lactulose, sorbitol, mannitol | Osmotic water retention; lactulose/sorbitol are fermented to organic acids. | Constipation; lactulose for hepatic encephalopathy. |
| Saline osmotics | Magnesium hydroxide, magnesium citrate, magnesium sulfate; sodium phosphate | Poorly absorbed ions retain water and may trigger cholecystokinin/motility effects. | Short-term constipation or procedural evacuation; highest electrolyte/renal caution. |
| Rectal osmotics | Glycerol/glycerin suppositories; sodium phosphate enema | Local osmotic water shift plus rectal stimulation. | Selected rectal loading/rapid relief; do not use when obstruction or mucosal injury is suspected. |
1. Polyethylene glycol (PEG, macrogol)
PEG is a high-molecular-weight, non-absorbable polymer. It holds water in stool without substantial fermentation, so it usually causes less gas and cramping than lactulose. PEG 3350 powder without electrolytes is widely used for chronic constipation; larger-volume PEG-electrolyte solutions are used under specific protocols for bowel cleansing or faecal disimpaction.
| Indication | Common adult teaching dose | Important points |
|---|---|---|
| Occasional/chronic constipation: PEG 3350 | 17 g PO once daily, dissolved in about 120–240 mL (4–8 oz) of water or another permitted beverage. Titrate according to product and response. | Often acts in 1–3 days. Maintain hydration. Do not continue unexplained constipation treatment indefinitely without reassessment. |
| Faecal impaction / severe loading | Use a local adult disimpaction protocol; macrogol-with-electrolyte sachet doses and durations differ by formulation. | Assess for obstruction, severe pain and rectal pathology first. Monitor frail patients and those with fluid/electrolyte risk. |
| Bowel preparation | Large-volume PEG-electrolyte regimens are product- and procedure-specific (often split-dose protocols). | Only use prescribed instructions. Diabetes medicines, anticoagulants, diuretics and oral medicines timing may need adjustment. |
PEG advantages and adverse effects
- Advantages: minimal absorption, effective stool softening, relatively low systemic electrolyte effect when used appropriately, and less bacterial fermentation than lactulose.
- Common effects: bloating, nausea, abdominal discomfort, loose stool or diarrhoea.
- Serious warnings: stop and assess if severe abdominal pain, vomiting, marked distension, rectal bleeding, fainting or no bowel movement after an appropriate trial occurs.
- Interactions: diarrhoea and rapid transit may reduce absorption of oral medicines; separate critical oral medicines according to the product/local guidance.
2. Lactulose
Lactulose is a synthetic disaccharide of galactose and fructose. It is not digested in the small intestine. Colonic bacteria ferment it into low-molecular-weight organic acids, increasing luminal osmolality and lowering colonic pH. In hepatic encephalopathy, acidification converts absorbable ammonia (NH3) to ammonium (NH4+), which is less readily absorbed and is excreted in stool.
| Use | Common adult teaching dose | Treatment target / caution |
|---|---|---|
| Constipation | 15–30 mL PO daily (10–20 g when solution is 10 g/15 mL); may be titrated by response. Some product labels use 15–45 mL/day initially. | Target comfortable soft stool, not diarrhoea. Onset is often 24–48 h. Bloating and flatulence are frequent. |
| Hepatic encephalopathy | Common initial treatment: 30–45 mL PO 3–4 times daily, then titrate to 2–3 soft stools daily under clinical supervision. | Do not cause profuse diarrhoea: it produces dehydration, hypokalaemia and may worsen encephalopathy. In impaired consciousness, protect the airway and use specialist/ward protocol for enteral or rectal administration. |
Lactulose prescribing details
- Adverse effects: flatulence, abdominal cramps, nausea, diarrhoea, dehydration and electrolyte disturbance if overused.
- Diabetes: many lactulose solutions contain small amounts of other sugars; monitor glucose in susceptible patients, especially at high hepatic-encephalopathy doses.
- Contraindication/caution: bowel obstruction, galactosaemia or requirement for strict low-galactose diet (check the specific formulation), severe dehydration and suspected acute abdomen.
- Monitoring in hepatic encephalopathy: mental state, stool frequency, fluid balance, sodium/potassium, renal function and precipitating factors such as GI bleeding, infection, constipation, hypokalaemia and sedatives.
3. Magnesium-containing saline osmotics
Magnesium hydroxide (“milk of magnesia”), magnesium citrate and magnesium sulfate retain water in the lumen and may act within hours. Their speed makes them tempting for acute constipation, but magnesium can accumulate in renal impairment and cause hypotension, lethargy, respiratory depression, bradyarrhythmia and muscle weakness.
| Agent | Common adult teaching dose | Onset and safety |
|---|---|---|
| Magnesium hydroxide | For a 400 mg/5 mL suspension: 30–60 mL PO once daily, often at bedtime, for short-term constipation. Check product concentration. | Usually 30 min–6 h. Avoid or use specialist advice in eGFR reduction, frailty, heart block, dehydration and magnesium-restricted diets. |
| Magnesium citrate | Single-dose oral solutions vary widely by product; a common adult OTC range is 195–300 mL once. Follow the exact product label and do not repeat casually. | Often 30 min–6 h. Adequate clear-fluid intake is needed unless restricted. Avoid in kidney disease, heart failure, dehydration or suspected obstruction. |
| Magnesium sulfate | Not preferred for routine self-treatment; use only under a stated local protocol. | High risk of fluid/electrolyte shifts and hypermagnesaemia when renal clearance is impaired. |
4. Sodium phosphate
Sodium phosphate preparations are powerful saline osmotics used in some bowel-preparation or rectal-evacuation settings. They can raise serum phosphate and sodium while lowering calcium and potassium. Acute phosphate nephropathy, arrhythmia, seizures, shock and death have occurred after excessive doses or in susceptible patients. Therefore, sodium phosphate should never be treated as a routine “strong constipation medicine.”
| Route | Common adult teaching dose | Safety rule |
|---|---|---|
| Rectal sodium phosphate enema | Many adult products contain about 118 mL as one rectal dose; exact formulation varies. | Use only per product/local protocol. Do not use more than one dose in 24 hours without clinician direction. Never use in obstruction, dehydration, renal disease, heart failure or unexplained abdominal pain. |
| Oral sodium phosphate bowel preparation | Regimens are product-specific and should be prescribed for procedures only. | Prefer safer alternatives when renal/cardiac/electrolyte risk is present. Check all interacting medicines and fluid plan. |
Who is at high risk from phosphate preparations?
- Chronic kidney disease, acute kidney injury, dehydration or older/frail age.
- Heart failure, cirrhosis or restricted fluid intake.
- Patients taking diuretics, ACE inhibitors, ARBs or NSAIDs that can reduce renal perfusion.
- Baseline electrolyte disturbance, prolonged QT, seizures or inflammatory bowel disease.
- Repeated doses, overdose, retention of an enema or failure to drink the prescribed fluid.
5. Sorbitol, mannitol and glycerol
Sorbitol
Sorbitol is a poorly absorbed sugar alcohol that has an osmotic effect and may be fermented in the colon. It is sometimes used for constipation or with certain resins, but it can cause marked diarrhoea, cramping and dehydration. Avoid unsupervised high-dose use and use caution in patients with poor oral intake or electrolyte disturbance.
Mannitol
Mannitol is an osmotic agent but is not a standard routine oral laxative in modern practice. IV mannitol has entirely different indications (for example, selected raised intracranial/intraocular pressure situations) and must never be confused with a constipation treatment.
Glycerol/glycerin suppositories
Glycerol acts locally as a rectal osmotic agent and stimulant. A common adult teaching dose is one 2–3 g rectal suppository once; effect may occur within 15–60 minutes. It is useful for selected distal rectal stool but not for high bowel obstruction or severe faecal impaction without assessment. Avoid rectal agents with unexplained rectal bleeding, severe proctitis, neutropenia/thrombocytopenia where local policy restricts rectal manipulation, or suspected perforation.
Indications and correct agent selection
| Situation | Preferred osmotic direction | Important reasoning |
|---|---|---|
| Chronic idiopathic constipation | PEG 3350/macrogol, or lactulose if PEG unavailable/not tolerated. | Combine with fibre, fluid, activity and medication review where appropriate. Avoid lifelong unreviewed escalation. |
| Opioid-associated constipation | Often PEG plus a stimulant regimen; consider opioid-induced-constipation pathway if inadequate. | Review opioid need and rule out obstruction. Osmotic alone may be insufficient. |
| Faecal loading/impaction | Macrogol-electrolyte regimen or rectal/manual strategy according to assessed location and protocol. | Examine, assess obstruction and determine whether stool is rectal or proximal. Do not blindly stack multiple cathartics. |
| Hepatic encephalopathy | Lactulose, titrated to 2–3 soft stools/day; rifaximin may be added in recurrent disease under specialist care. | Find precipitants and avoid over-treatment diarrhoea/dehydration. |
| Bowel preparation before colonoscopy | Prescribed split-dose PEG-electrolyte regimen is commonly preferred. | Preparation quality determines diagnostic safety; follow procedure-specific timing and diet instructions exactly. |
| Need for rapid short-term relief | Consider a saline or rectal osmotic only after risk assessment. | Renal function, volume status, cardiac status and obstruction risk decide safety. |
Contraindications and precautions
- Absolute or strong red flags: known/suspected mechanical obstruction, perforation, acute surgical abdomen, severe inflammatory colitis/toxic megacolon, severe dehydration or unexplained severe abdominal symptoms.
- Renal impairment: avoid magnesium and phosphate preparations unless specifically directed; PEG/lactulose may still require fluid and electrolyte monitoring in frail patients.
- Heart failure/cirrhosis: sodium load and large fluid volumes may worsen status; choose carefully and coordinate fluid plan.
- Pregnancy and paediatrics: do not copy adult doses. Use pregnancy- and child-specific guidance; assess constipation cause, hydration and product licensing.
- Older adults: high risk of dehydration, falls, delirium and electrolyte abnormality, especially with diuretics or polypharmacy.
Adverse effects and monitoring table
| Class | Common adverse effects | Potential serious harm / monitoring |
|---|---|---|
| PEG | Bloating, nausea, loose stool, cramps | Dehydration with excessive diarrhoea; monitor intake/electrolytes in high-risk patients. |
| Lactulose | Flatulence, bloating, cramps, diarrhoea | Hypernatraemia/hypokalaemia, dehydration; monitor stool target and mental state in hepatic encephalopathy. |
| Magnesium salts | Diarrhoea, cramps, nausea | Hypermagnesaemia, hypotension, bradycardia, respiratory depression; check renal function and magnesium if symptomatic. |
| Sodium phosphate | Cramps, diarrhoea, thirst | Hyperphosphataemia, hypocalcaemia, hypernatraemia, AKI, arrhythmia, seizures; avoid in high-risk patients. |
| Rectal agents | Rectal discomfort, urgency | Mucosal trauma, retention/electrolyte effects with phosphate enemas; avoid inappropriate rectal manipulation. |
Clinical cases
Case 1: chronic constipation in an older person with CKD
An older patient with eGFR 25 mL/min/1.73 m² requests magnesium citrate because it “works quickly.” Magnesium may accumulate and produce dangerous toxicity. Assess red flags and medicines, address hydration and mobility, and choose a safer constipation plan such as PEG/macrogol under clinical guidance rather than a magnesium or phosphate cathartic.
Case 2: cirrhosis with confusion and constipation
This may be hepatic encephalopathy. Start a monitored lactulose plan following local protocol and titrate to 2–3 soft stools daily—not continuous diarrhoea. Assess for GI bleeding, infection, dehydration, constipation, sedatives, hypokalaemia and renal dysfunction; these can precipitate or worsen encephalopathy.
Case 3: abdominal distension, vomiting and no flatus
Do not prescribe a laxative. This is obstruction/ileus until proven otherwise. Perform ABCDE assessment, resuscitate as necessary, insert a nasogastric tube only when clinically indicated, obtain urgent surgical review and appropriate imaging.
High-yield revision points
- Osmotic laxatives retain water in the bowel; they do not correct an obstructed bowel.
- PEG/macrogol is minimally absorbed and is widely useful for constipation and bowel preparation.
- Lactulose is both an osmotic laxative and an ammonia-lowering treatment for hepatic encephalopathy.
- For hepatic encephalopathy, titrate lactulose to 2–3 soft stools/day; excessive diarrhoea is harmful.
- Magnesium salts can cause hypermagnesaemia in renal impairment.
- Sodium phosphate can cause major electrolyte disturbance and acute kidney injury; never repeat or use casually in high-risk patients.
- All adult doses require product, indication and patient-specific verification.
